GlionAI Biotherapeutics
Computational drug design and molecular-glue therapeutics development.
Health Tech & Life Sciences
Non Active, Jun 2026 ceased to operate
Company Overview
Snapshot
Founded in May 2025, GlionAI Biotherapeutics operates with 1–10 employees. The company ceased operations in June 2026.
Business overview
GlionAI Biotherapeutics specializes in developing computational tools for drug design and advancing molecular-glue therapeutics programs. The company focuses on the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development, serving industries involved in pharmaceutical research and development.
Log in to access full profile ›Company Intelligence Q&A
- What is GlionAI Biotherapeutics' primary focus?
- GlionAI Biotherapeutics focuses on computational drug design and the development of molecular-glue therapeutics programs.
- When was GlionAI Biotherapeutics founded?
- GlionAI Biotherapeutics was founded in May 2025.
- What is the current status of GlionAI Biotherapeutics?
- GlionAI Biotherapeutics is non-active and ceased to operate in June 2026.
- In which sector does GlionAI Biotherapeutics primarily operate?
- GlionAI Biotherapeutics operates primarily in the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- What is the employee count for GlionAI Biotherapeutics?
- GlionAI Biotherapeutics has 1–10 employees.